Home  /  Resource Library  /  Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Key point – patients with relapsed/refractory DLBCL who received blinatumomab overall response was 43% (CR was 19%).